Codon

JANUARY 21, 2024

Human challenge trials were an indispensable part of the development of the malaria vaccine, R21/Matrix-M, endorsed by the World Health Organization last October. But for all of their benefits, human challenge trials have their drawbacks. Jake himself has participated in both Zika and Shigella challenge trials.

Vaccine 111

Vaccine Trials Disease Virus 111

The Pharma Data

DECEMBER 4, 2020

Having beat the United States to emergency authorization may pressure American regulators, who are already taking heat for not moving faster to get doses to people, the Times reported. Around the world, researchers are testing 57 vaccines in clinical trials, and nearly 100 others are being tested in animals or cell, the Times reported.

Long-Term Care Facilities 52

Long-Term Care Facilities Vaccine Nurses Hospitals 52

The Pharma Data

DECEMBER 3, 2020

Having beat the United States to emergency authorization may pressure American regulators, who are already taking heat for not moving faster to get doses to people, the Times reported. Around the world, researchers are testing 57 vaccines in clinical trials, and nearly 100 others are being tested in animals or cell, the Times reported.

Hospitals 52

Hospitals Long-Term Care Facilities Vaccine Nurses 52

Altus Drug Development

MAY 31, 2022

By changing the focus of healthcare from profits to the well-being of patients, the healthcare world can start a virtuous cycle that benefits patients, doctors, and pharmaceutical manufacturers alike. Developing novel methodologies can help nurses and other people in charge of delivering care to better handle the treatment of patients.

Pharmaceuticals 52

Pharmaceuticals Packaging Treatment Doctors 52

The Pharma Data

DECEMBER 2, 2020

Having beat the United States to emergency approval of a coronavirus vaccine may pressure American regulators, who are already taking heat for not moving faster to get doses to people, The New York Times reported. Doctors say this reflects India’s younger and leaner population. Hospitalizations reach record high.

Vaccine 40

Vaccine Long-Term Care Facilities Hospitals Nurses 40

The Pharma Data

JUNE 18, 2021

Additionally, there are other ongoing company-sponsored and investigator-initiated trials exploring the potential of ibrutinib and venetoclax in combination for CLL treatment, including the Phase 3 GLOW study. IMBRUVICA is the most comprehensively studied BTK inhibitor, with more than 150 ongoing clinical trials.

Treatment 40

Treatment FDA FDA Approval Therapies 40

The Pharma Data

JUNE 18, 2021

The GLOW study is a randomized, open label Phase 3 trial comparing progression-free survival in patients treated with either I+V or C+O as assessed by an Independent Review Committee. IMBRUVICA is the most comprehensively studied BTK inhibitor, with more than 150 ongoing clinical trials. About the GLOW Study.

Treatment 52

Treatment Therapies FDA FDA Approval 52